Search filters

Filters
Clear All

Phase

  • 8
  • 9
  • 13
  • 7
  • 11
  • 52
  • 25
  • 1
  • 11
  • 40

Found 52 Breast Cancer trials

A listing of Breast Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

18 years - 99 years
Female
Interventional
The purpose of this study is to test a new scanner device that combines two types of imaging called Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DPT) for imaging of a radioactive imaging drug called 18F-Fluoroestradiol (FES), as a diagnostic device for imaging estrogen receptor (ER) positive breast …
 Study of INO-5401 Alone or INO-5401 in Combination with INO-9012 Followed by Electroporation in Adults with BRCA1 or BRCA2 Mutations
18 years - 99 years
All genders
Phase 1
The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine …
 A Randomized   Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+)  HER2 (-) Breast Cancer
18 years - 99 years
All genders
Phase 3
Interventional
The purpose of the study is to evaluate whether SAR439859 (an experimental hormonal treatment), in combination with palbociclib is a better option compared to letrozole (a standard hormonal treatment), in combination with palbociclib, in terms of efficacy and tolerance for treating patients with ER (+), HER2 (-) breast cancer. Eligible …
18 years - 99 years
All genders
Phase 2
This study is being done to evaluate if participants with HER2-positive breast cancer who have no cancer remaining at surgery after 12 weeks of chemotherapy and two HER-targeting therapies eliminate further chemotherapy after surgery. Eligible subjects would be those with HER2-positive breast cancer.
 A Randomized  Open Label Pilot Trial of a Biomarker Guided Strategy of Cardioprotection in Patients with Lymphoma or Breast Cancer Treated with Anthracyclines
18 years - 99 years
All genders
Phase 1
You will be receiving anthracycline-based chemotherapy (Adriamycin/doxorubicin) as part of your cancer treatment plan. Although anthracycline-based chemotherapy is effective in treating cancer, it can damage your heart. This study has two goals. The first goal is to see if we can identify who is most at risk for this heart …
 FES PET/CT in Endocrine Refractory Breast Cancer
18 years - 99 years
All genders
Patients with recurrent or metastatic ER+ breast cancer, who have failed prior endocrine therapy may be eligible for this study.  Patients may participate in this study, if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. …
 Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O)
18 years - 99 years
Female
Prior participants of ROSY-O study
99 years or below
All genders
Phase 1
LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …
99 years or below
All genders
Phase 1
This study recruits participants directly from Penn Medicine clinics, during time of their clinical biopsies. Up to 40 participants with known or suspected primary or metastatic breast cancer who meet eligibility requirements for this study will undergo FTT PET/CT study imaging. Each PET/CT scan will include an injection of up …
 UPCC 24116: A Phase II Pilot Trial of Hydroxychloroquine  Everolimus or the Combination for Prevention of Recurrent Breast Cancer
99 years or below
All genders
Phase 2
The main purpose of this study is to: 1) determine the feasibility of giving hydroxychloroquine, everolimus or the combination to people with disseminated tumor cells detected in their bone marrow. 2) determine how tolerable these drugs are in people who have completed treatment for breast cancer. 3) determine how well …